Molecular mechanisms To protect malaria infection by vaccine using antigen / hsp70 fusion protein

分子机制 利用抗原/hsp70融合蛋白疫苗保护疟疾感染

基本信息

项目摘要

APCs can internalize some types of exogenous antigens for processing and presentation on MHC class I molecules, which is referred to as cross-presentation. It is known that peptides associated with hsp70 can be presented in this manner to induce specific CTLs. To determine the cross-presentation pathway of hsp70 associated peptides, we generated hsc70-OVA_<257-264> (hsc70-OVA) fusion protein, which could induce specific CTL in vivo. CD8^+ T cells (OT-1 cells) were isolated from K_b-restricted OVA_<257-264> specific TCR transgenic mice (OT-1). RMA, RMA-S (TAP-) or bone-marrow derived DC, which were generated from C57BL/6 or TAP KO mice, were used as ARC. To determine whether APC can cross-present hsc70-OVA, we measured IFN-γ production from OT-1 cells in response to hsc70-OVA-pulsed ARC, and the expression of K_b-OVA_<257-264> complex on APC using 25D1.16 mAb. Our results showed that, 1) OT-1 cells produced IFN-γ in response to hsc70-OVA-pulsed TAP-negative 8M-DC, 2) High levels of K_b-OVA_<257-264> complex were detected on hsc70-OVA-pulsed RMA. The levels of K_b-OVA_<257-264> complexes detected on hsc70-OVA-pulsed RMA-S were similar to RMA. 3) The expression level of K_b-OVA_<257-264> complexes on RMA was only partially Inhibited by brefeldin A. 4) The expression of K_b-OVA_<257-264> complexes on RMA was completely inhibited by pretreatment of pCMBS, which is the inhibitor of fluid phase endocytosis (macropinocytosis). However, IFN-γ production from OT-1 T cells were not inhibited when BM-DC were treated with pCMBS. 5) IFN-γ production from OT-1 T cells were reduced when BM-DC were pulsed with hsc70-OVA in the presence of hsc70. Our results suggest that there are two distinct pathways of endocytosis of hsc, macropinocytosis and receptor-mediated endocytosis, and that there existed TAP-independent cross-presentation pathway of hsc associated peptide.
APC可以将某些类型的外生元素内化,以表现为Olecuss I分子,以至于可以以这种方式呈现与Hsp70相关的肽以诱导特定的CTL来确定HSP70相关肽的交叉态度。 -ova_ <257-264>(HSC70-OVA)在Vivo中。从C57BL/6或Tap O Mice产生的RMA-S(Tap-)或骨row衍生的DC被用作APC跨至跨量的HSC70-ova k_b-ova_ <257-264 > APS 25D1的复合物在HSC70-OVA脉冲的8M-DC中产生IFN-1细胞,在HSC70-OVA型RMA上检测到高水平的-264>复合物K_B-OVA_ <257-264>在HSC70-OVA脉冲RMA-S上检测到的复合物与RMA上的K_b-overa_ <257-264>复合物相似。 RMA上的K_b-ova_ <257-264>由PCMB完全抑制,这是液相内吞作用的抑制剂(巨型细胞增多症)。在HSC70的情况下,PCMBS。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HONMA Kiri其他文献

IRF4 controls cytokine signals and plays critical roles for proliferation and differentiation of CD8+ T cells.
IRF4 控制细胞因子信号,对 CD8 T 细胞的增殖和分化发挥关键作用。
  • DOI:
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    MIYAKODA Mana;HONMA Kiri;KIMURA Daisuke;KIMURA Kazumi;MATSUYAMA Toshifumi;YUI Katsuyuki
  • 通讯作者:
    YUI Katsuyuki
IL-27-producing malaria-specific CD4+ T cells regulate protective imune responses
产生 IL-27 的疟疾特异性 CD4 T 细胞调节保护性免疫反应
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    KIMURA Daisuke;MIYAKODA Mana;KIMURA Kazumi;HONMA Kiri;HARA Hiromitsu;YOSHIDA Hiroki;YUI Katsuyuki
  • 通讯作者:
    YUI Katsuyuki

HONMA Kiri的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HONMA Kiri', 18)}}的其他基金

Th2 independent NB expulsion by natural helper cells
自然辅助细胞对 Th2 独立 NB 的排出
  • 批准号:
    23590488
  • 财政年份:
    2011
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Regulation of IL12 production in the induction of protective immune response against Leishmania infection
IL12 产生在诱导针对利什曼原虫感染的保护性免疫反应中的调节
  • 批准号:
    20590424
  • 财政年份:
    2008
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New recognition of Leishmania major by infected macrophages
受感染的巨噬细胞对大型利什曼原虫的新识别
  • 批准号:
    18590401
  • 财政年份:
    2006
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

基于短寿蛋白肿瘤疫苗诱导的抗瘤作用及其机制的研究
  • 批准号:
    30771999
  • 批准年份:
    2007
  • 资助金额:
    33.0 万元
  • 项目类别:
    面上项目

相似海外基金

Heat shock protein gp96 and Treg responses
热休克蛋白 gp96 和 Treg 反应
  • 批准号:
    9606843
  • 财政年份:
    2018
  • 资助金额:
    $ 2.3万
  • 项目类别:
Molecular chaperones and immune tolerance
分子伴侣和免疫耐受
  • 批准号:
    9310818
  • 财政年份:
    2009
  • 资助金额:
    $ 2.3万
  • 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
  • 批准号:
    8537837
  • 财政年份:
    2007
  • 资助金额:
    $ 2.3万
  • 项目类别:
2007 Antigen Cross-Presentation
2007 年抗原交叉展示
  • 批准号:
    7271580
  • 财政年份:
    2007
  • 资助金额:
    $ 2.3万
  • 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
  • 批准号:
    8394481
  • 财政年份:
    2007
  • 资助金额:
    $ 2.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了